Kernal Biologics
- Founded: 2016
- Location: Cambridge, MA
- Employee range: 11 - 50
- Funding: $25M A Jul 2022; $10.5M seed 2020
- Investors: Hummingbird Ventures. Amgen Ventures, HBM Genomics, Civilization Ventures
kernalbio.com linkedin.com job board
Short description:
mRNA Technology
Drug notes:
Contact us to add description: recruit@workinbiotech.com
Long description:
Kernal Biologics is developing mRNA therapeutics for diseases like COVID and cancer. mRNA therapeutics have much potential to deliver instructions to cells to produce therapeutic proteins, but the therapeutics are limited by effective delivery. Using their patented engineering methods and a clinically validated delivery system, Kernal is identifying therapeutic mRNAs that can be targeted to a diseased tissue and offer hyper-selective activation. This involves mining datasets to identify targetable nuances in the genetic code unique to different cell types and inserting those signatures into designer mRNAs. Kernel refers to these mRNAs, which are delivered via lipid nanoparticles to achieve specificity, as ‘mRNA 2.0’. The proteins made by cells decoding the mRNA can promote healing or suppress disease.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com